Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD/MAD Safety and PK Study of LY3541860 in Healthy Participants
jRCT2031210359Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2021
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY3541860 in None (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Number of participants with treatment-emergent adverse events (TEAEs) related to study drug, Number of participants with treatment-emergent serious adverse events (SAEs) related to study drug and 1 more. Started Nov 2021; status: completed.
02
Drugs
LY3541860
Beyond the preview
Go deeper on jRCT2031210359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210359.